SGLT2 Inhibitor with and without ALDosterone AntagonIst for Heart Failure with Preserved Ejection Fraction: Design Paper
ESC Heart Failure · 2025
DOI: 10.1002/ehf2.15294 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, 2025. Verfasst von João Pedro Ferreira und 26 weiteren Autor:innen. Beteiligte Einrichtung: RISE-Health, Departamento de Cirurgia e Fisiologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Heart Failure, Mineralocorticoid Receptor Antagonists. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca, FCT Fundação para a Ciência e Tecnologia, Fundação para a Ciência e a Tecnologia.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Sodium glucose co-transporter 2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonists (MRA) reduce heart failure (HF) events in patients with heart failure and mildly reduced or preserved ejection fraction (HFmr/pEF). The randomized comparison of SGLT2i/MRA combination versus SGLT2i or MRA alone requires further testing in HFmr/pEF.
Aims
To compare the efficacy (NT-proBNP change as primary outcome) and safety (potassium, creatinine, and blood pressure changes) of dapagliflozin/spironolactone combination versus dapagliflozin alone (primary comparison) and spironolactone alone (exploratory comparison).
Methods
SOGALDI-PEF (SOdium-Glucose cotransporter 2 inhibitor, ALDosterone AntagonIst, or both for heart failure with preserved ejection fraction; NCT05676684), a proof-of-concept investigator-initiated two-centre randomized cross-over trial comparing three arms (dapagliflozin, spironolactone, or both) for three periods of 12 weeks each intercalated by a wash-out period of 4 weeks. After two independent trials demonstrating efficacy of SGLT2i in HFmr/pEF, a mid-trial protocol amendment dropped the spironolactone alone sequence and reduced the wash-out period to 1 week. A sample size of 108 patients was estimated to provide 80% power, at a 0.05 alfa level, to detect a 0.15 LogNT-proBNP difference between the spironolactone/dapagliflozin combination and dapagliflozin alone sequence.
Results
SOGALDI-PEF included 108 patients with a median age of 76 years, 57% women, 42% with atrial fibrillation, 46% with type 2 diabetes, 33% having an eGFR below 60 mL/min/1.73m2, and 93% having an ejection fraction ≥ 50%. The median serum potassium was 4.3 mmol/L, and the median NT-proBNP was 764 pg/mL. Most patients were treated with renin–angiotensin blockers (68%), beta-blockers (70%) and loop diuretics (69%). Compared to other HFmr/pEF trials, SOGALDI-PEF patients were older, were more frequently women, had a high prevalence of atrial fibrillation, and had more often a preserved ejection fraction.
Conclusions
SOGALDI-PEF will be the first trial in HFmr/pEF to test the combination of dapagliflozin/spironolactone vs dapagliflozin alone in a randomized manner. SOGALDI-PEF will provide information on the potential efficacy and safety of concomitant administration of spironolactone with dapagliflozin vs dapagliflozin alone in an elderly population with HFmr/pEF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- RISE-Health, Departamento de Cirurgia e Fisiologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.
- Université de Lorraine INSERM, Centre d'Investigations Cliniques 1433, CHRU de Nancy, Inserm 1116 and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network, Nancy, France.
- Serviço de Medicina Interna, Unidade Local de Saúde São João, Porto, Portugal.
- Serviço de Cardiologia, Unidade Local de Saúde Gaia/Espinho Gaia, Vila Nova de Gaia, Portugal.
- Serviço de Patologia Clínica, Unidade Local de Saúde São João, Porto, Portugal.
- Serviço de Medicina Interna, Unidade Local de Saúde Gaia/Espinho Gaia, Vila Nova de Gaia, Portugal.
Förderung
- AstraZeneca
- FCT Fundação para a Ciência e Tecnologia
- Fundação para a Ciência e a Tecnologia
Zitieren
APA
Ferreira, J. P., Vasques-Nóvoa, F., Saraiva, F., Oliveira, A. C., Almeida, J., Batista, A. B., Barbosa, A., Ferreira, A. F., Costa, C., Santos-Ferreira, D., Friões, F., Goncalves, C., Guimarães, J. T., Leite, M., Marques, P., Mascarenhas, J., Matos, M. I., Pereira, C., Rodrigues, P., …, & Leite-Moreira, A. (2025). SGLT2 Inhibitor with and without ALDosterone AntagonIst for Heart Failure with Preserved Ejection Fraction: Design Paper. ESC Heart Failure. https://doi.org/10.1002/ehf2.15294
Vancouver
Ferreira JP, Vasques-Nóvoa F, Saraiva F, Oliveira AC, Almeida J, Batista AB, et al. SGLT2 Inhibitor with and without ALDosterone AntagonIst for Heart Failure with Preserved Ejection Fraction: Design Paper. ESC Heart Failure. 2025. doi:10.1002/ehf2.15294
BibTeX
@article{Ferreira2025,
author = {Ferreira, João Pedro and Vasques-Nóvoa, Francisco and Saraiva, Francisca and Oliveira, Ana C and Almeida, Jorge and Batista, Ana Beatriz and Barbosa, Arsénio and Ferreira, Ana Filipa and Costa, Cátia and Santos-Ferreira, Diogo and Friões, Fernando and Goncalves, Cândida and Guimarães, João Tiago and Leite, Marta and Marques, Pedro and Mascarenhas, Joana and Matos, Maria Inês and Pereira, Catarina and Rodrigues, Pedro and Sharma, Abhinav and Silva, Gualter and Pereira-Sousa, Inês and Sousa, Carla and Zannad, Faiez and Pimenta, Joana and Fontes-Carvalho, Ricardo and Leite-Moreira, Adelino},
title = {SGLT2 Inhibitor with and without ALDosterone AntagonIst for Heart Failure with Preserved Ejection Fraction: Design Paper},
journal = {ESC Heart Failure},
year = {2025},
doi = {10.1002/ehf2.15294}
}
EUVIMED